Heron Capital

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, that focuses on developing innovative devices for the treatment of degenerative mitral valve disease (DMR). Founded in 2007, the company has created the NeoChord Artificial Chordae Delivery System, a disposable device designed for minimally invasive mitral valve repair. This system allows surgeons to replace damaged chordae through a small incision of 2 to 3 inches between the ribs, enabling the procedure to be performed on a beating heart. This approach contrasts sharply with traditional methods, which typically involve larger incisions and stopping the heart, thus reducing recovery time and associated complications. NeoChord's technology aims to improve surgical outcomes for patients suffering from severe mitral regurgitation, which can lead to serious conditions such as atrial fibrillation and congestive heart failure.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Scale Computing, Inc. specializes in edge computing, virtualization, and hyperconverged infrastructure solutions tailored for midsized companies. The company’s flagship product, the HC3 platform, consolidates servers, storage, and virtualization into a single, integrated system that simplifies management and enhances application performance. By leveraging self-healing and automation technologies, HC3 minimizes downtime and reduces the complexities associated with traditional IT infrastructure, such as separate virtualization and disaster recovery software. This approach allows organizations to improve application uptime while lowering overall costs. Founded in 2007 and headquartered in Indianapolis, Indiana, Scale Computing aims to enable clients to focus on application management rather than infrastructure concerns.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

IDEV Technologies is a medical device company dedicated to developing innovative products for endovascular and interventional applications, particularly in the fields of interventional radiology, gastroenterology, vascular surgery, and cardiology. The company markets SUPERA, a unique self-expanding nitinol stent designed with a patented interwoven structure that enhances flexibility, radial strength, and resistance to kinking and crushing. SUPERA has received approval for treating biliary strictures in the United States. Additionally, IDEV is actively enrolling patients in the SUPERB IDE trial to evaluate the stent's safety and efficacy for use in the superficial femoral artery.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Atlantis has designed a software system known as the Virtual Abutment Design (VAD) system. VAD allows their technicians to design abutments with a certainty and precision previously unknown to implant dentistry. The following is an overview of the Atlantis VAD and titanium machining process. The same process is followed by their technicians for single and multiple unit cases.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.

AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.